Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01498328 · ClinicalTrials.gov registry record · Phase 2
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
A Phase 2 study of Glioblastoma and Recurrent Glioblastoma, sponsored by Celldex Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
- 20
- Study locations
NCT01498328 is a Phase 2 study of Glioblastoma and Recurrent Glioblastoma that has completed, run by Celldex Therapeutics. The registered enrollment target is 127 participants, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (18% higher). The trial reports 20 study locations across 10 states.
The verdict
NCT01498328, a Phase 2 study of Glioblastoma and Recurrent Glioblastoma, has completed, sponsored by Celldex Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth of tumors) of patients with relapsed EGFRvIII positive glioblastoma.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Rindopepimut (CDX-110) with GM-CSF
- DRUG KLH
Study Locations (20)
California
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- University of Southern California (USC) Norris Comprehensive Cancer Center - Los Angeles
- UC Irvine Chao Family Comprehensive Cancer Center - Orange
- University of California San Francisco - San Francisco
- Stanford Cancer Institute, Stanford University - Stanford
Florida
- Memorial Cancer Institute - Hollywood
- Orlando Health, Inc. - Orlando
- Tampa General Hospital - Tampa
Illinois
- Rush University Medical Center - Chicago
- University of Chicago - Chicago
- NorthShore University Health System - Evanston
Georgia
- Piedmont Atlanta Hospital - Atlanta
- Atlanta Cancer Care - Atlanta
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
- Sparrow Cancer Center - Lansing
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- St. Joseph's Hospital and Medical Center / Barrow Neurological Institute - Phoenix
Colorado
- University of Colorado, Denver - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-05-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01498328
The ClinicalTrials.gov registry entry for NCT01498328 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target (18% higher). The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01498328 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT01498328 about?
NCT01498328 is a clinical study titled "A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma". The purpose of this research study is to find out whether adding an experimental vaccine called rindopepimut (also known as CDX-110) to the commonly used drug bevacizumab can improve progression free survival (slowing the growth of tumors) of patients with relapsed EGFRvIII positive glioblastoma.
What is the current status of trial NCT01498328?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2011-12. Estimated completion is 2016-05-17.
What conditions does trial NCT01498328 study?
This clinical trial studies the following conditions: Glioblastoma, Recurrent Glioblastoma, Gliosarcoma, Giant Cell Glioblastoma, Small Cell Glioblastoma.
What interventions are being tested in trial NCT01498328?
The interventions under investigation include: Bevacizumab (DRUG), Rindopepimut (CDX-110) with GM-CSF (DRUG), KLH (DRUG).
Who is sponsoring clinical trial NCT01498328?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01498328 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
RECRUITING · Phase 2
-
Venous Thromboembolism Prevention in Outpatients With Glioma
RECRUITING · Phase 2
-
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
RECRUITING · Phase 2
-
Surgical Pembro +/- Olaparib w TMZ for rGBM
RECRUITING · Phase 2
-
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
RECRUITING · Phase 2
-
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.